scRNA-seq for HCC lesions scheduled to neoadjuvant anti–PD-1 monotherapy was performed to evaluate the role of HMGB2+ CD8+ T cells in ICI efficacy from our previous study (26). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.